Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed drug in pediatric subjects with migraines. After completion of a portion of the study (Panels A and B), a regulatory agency issued an amended request that the 12-17 year old age group studied should include a similar number of male and female subjects. Therefore, the study was amended to add an additional panel of subjects (Panel C) to ensure gender balance specifically in this age group.
Age
6 - 17 years
Sex
ALL
Healthy Volunteers
No
Start Date
December 17, 2007
Primary Completion Date
September 17, 2010
Completion Date
September 17, 2010
Last Updated
April 19, 2024
31
ACTUAL participants
rizatriptan benzoate (5 mg)
DRUG
rizatriptan benzoate (10 mg)
DRUG
Rizatriptan 5 mg Placebo
DRUG
Rizatriptan 10 mg Placebo
DRUG
Lead Sponsor
Organon and Co
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05690737